Patents Assigned to Pharmacia Corporation
  • Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
    Publication number: 20050153965
    Abstract: The present invention relates to compounds, and prodrugs thereof, composition and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhibit certain proteases of the coagulation cascade.
    Type: Application
    Filed: December 3, 2004
    Publication date: July 14, 2005
    Applicant: Pharmacia Corporation
    Inventors: Michael South, Brenda Case, Danny Garland, Michael Hayes, Horng-Chih Huang, Wei Huang, Darin Jones, William Neumann, John Parlow, David Reitz, Melvin Rueppel, Ronald Webber
  • Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
    Patent number: 6916847
    Abstract: The invention relates to polycyclic aryl and heteroaryl substituted 4-pyrone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: July 12, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Chun C. Ma, Kevin J. Koeller, Hayat K. Rahman, William L. Neumann
  • Amidino compounds useful as nitric oxide synthase inhibitors
    Patent number: 6914158
    Abstract: The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: July 5, 2005
    Assignee: Pharmacia Corporation
    Inventors: Ronald Keith Webber, Richard C. Durley, Alok K. Awasthi, Arija A. Bergmanis, Kam F. Fok, Scott S. Ganser, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Brian S. Hickory, Pamela T. Manning, Michael Mao, Alan E. Moormann, Barnett S. Pitzele, Michelle A. Promo, Richard R. Schartman, Jeffrey A. Scholten, Jeffrey S. Snyder, Mihaly V. Toth, Mahima Trivedi, Sofya Tsymbalov, Foe Siong Tjoeng
  • Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
    Publication number: 20050143371
    Abstract: The present invention provides novel compounds that are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2 and analogues thereof and pharmaceutical compositions and kits that include these compounds.
    Type: Application
    Filed: July 20, 2004
    Publication date: June 30, 2005
    Applicant: Pharmacia Corporation
    Inventors: Marvin Meyers, David Reitz, David Anderson, Shridhar Hegde, Matthew Mahoney
  • Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
    Publication number: 20050137220
    Abstract: A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject a beta-carboline MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 20, 2004
    Publication date: June 23, 2005
    Applicant: Pharmacia Corporation
    Inventors: David Anderson, Ingrid Buchler, Shridhar Hegde, Matthew Mahoney, Marvin Meyers, David Reitz, John Trujillo, William Vernier, Kun Wu
  • Method of making tricyclic aminocyanopyridine compounds
    Patent number: 6909001
    Abstract: A method of making aminocyanopyridine compounds which are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2 is described.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: June 21, 2005
    Assignee: Pharmacia Corporation
    Inventors: David R. Anderson, Shridhar G. Hegde, Stephen A. Kolodziej, William F. Vernier, Emily J. Reinhard
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Patent number: 6908919
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: June 21, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Brenda L. Case, Thomas A. Dice, Ricky L. Fenton, Gary W. Franklin, Michael J. Hayes, Horng-Chih Huang, Wei Huang, Darin E. Jones, Carrie L. Kusturin, Richard J. Lindmark, Scott A. Long, William L. Neumann, David B. Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Matthew W. Mahoney, John J. Parlow, Melvin L. Rueppel
  • Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
    Publication number: 20050131028
    Abstract: A method is disclosed for providing extended duration treatment or prevention of pain, inflammation and inflammation-related disorders in a subject in need of such extended duration treatment or prevention by administering to the subject a Cox-2 selective inhibitor having certain added substituent groups. Also disclosed is a method for extending the duration of the plasma half-life of diaryl-substituted Cox-2 selective inhibitors by substituting halogen, haloalkyl, haloalkoxy, alkyl, nitrile, cyano or alkoxy groups at certain positions on the diaryl-substituted rings of the inhibitor molecule. A novel composition comprising such extended duration Cox-2 selective inhibitors is also disclosed.
    Type: Application
    Filed: September 9, 2004
    Publication date: June 16, 2005
    Applicant: Pharmacia Corporation
    Inventors: Jeffery Carter, Bernard Hummel
  • Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants
    Patent number: 6906068
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrimidinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: June 14, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Ashton T. Hamme, II, William L. Neumann, Darin E. Jones
  • Method of using (H+/K+) ATPase inhibitors as antiviral agents
    Patent number: 6906078
    Abstract: A class of compounds which are (H+/K+)ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III: wherein D is N or CH; wherein R7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, carboxyl, alkanoyl, nitro, amine, alkylamine, dialkylamine, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R10 and R11 are independently selected from hydrido and alkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: June 14, 2005
    Assignee: Pharmacia Corporation
    Inventors: Alan E Moorman, Daniel P Becker, Daniel L Flynn
  • Lactone integrin antagonists
    Patent number: 6906051
    Abstract: The present invention relates to a class of compounds represented by the Formula I: or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the ?V?3 and/or the ?V?5 integrin.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: June 14, 2005
    Assignee: Pharmacia Corporation
    Inventors: Peter Ruminiski, Thomas D. Penning, Lan Jiang, Balekudru Devadas, Thomas Rogers, Jennifer VanCamp, Chester Yuan
  • Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
    Publication number: 20050119262
    Abstract: The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.
    Type: Application
    Filed: August 17, 2004
    Publication date: June 2, 2005
    Applicant: Pharmacia Corporation
    Inventor: Martin Wax
  • Cyclic sulfone containing retroviral protease inhibitors
    Publication number: 20050119257
    Abstract: The present invention relates to cyclic sulfone moiety-containing hydroxyethylamine protease inhibitor compounds and pharmaceutical or method of use therefor, particularly as an inhibitor of HIV protease.
    Type: Application
    Filed: September 2, 2004
    Publication date: June 2, 2005
    Applicants: G.D. Searle & Co., Pharmacia Corporation (Monsanto Company)
    Inventors: Deborah Bertenshaw, Daniel Getman, Robert Heintz, John Talley, Kathryn Reed, Robert Chrusciel, Michael Clare
  • Cycloalkyl alkanoic acids as integrin receptor antagonists
    Patent number: 6900232
    Abstract: The present invention relates to a class of compounds represented by the Formula I Wherein A1 is a pyridinyl of the formula optionally substituted by one or more Rk selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino alkylamino, halogen, acylamino, sulfonamide and —COR; and R is hydroxy, alkoxy, alkyl or amino; and pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the ?v?3 and/or ?v?5 integrin.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: May 31, 2005
    Assignee: Pharmacia Corporation
    Inventors: Ish Kumar Khanna, Michael Clare, Alan F. Gasiecki, Thomas Rogers, Barbara Chen, Mark Russell, Hwang-Fun Lu
  • Anilino liver X-receptor modulators
    Patent number: 6900244
    Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: May 31, 2005
    Assignee: Pharmacia Corporation
    Inventors: Jennifer Ann Van Camp, James W. Malecha, Julie M. Miyashiro, Gary A. DeCrescenzo, Joe T. Collins, Monica J. Kalman
  • 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
    Publication number: 20050113451
    Abstract: The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
    Type: Application
    Filed: November 1, 2004
    Publication date: May 26, 2005
    Applicant: Pharmacia Corporation
    Inventors: Donald Hansen, Ronald Webber, Barnett Pitzele, James Sikorski, Mark Massa, Timothy Hagen, Margaret Grapperhaus, Lijuan Wang, Arija Bergmanis, Steven Kramer, E. Hallinan
  • Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
    Publication number: 20050113409
    Abstract: A method is described for the prevention or treatment of pain, inflammation, and inflammation-related disorders in a subject in need of such prevention or treatment, the method comprising administering to the subject a cyclooxygenase-2 selective inhibitor in combination with a nitric oxide-donating agent. Also described are therapeutic and pharmaceutical compositions and kits that are useful in the present invention.
    Type: Application
    Filed: September 2, 2004
    Publication date: May 26, 2005
    Applicant: Pharmacia Corporation
    Inventors: Jane Connor, Pamela Manning
  • Process for making substituted pyrazoles
    Patent number: 6897318
    Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: May 24, 2005
    Assignee: Pharmacia Corporation
    Inventors: Kimberly K. Allen, Dennis K. Anderson, John E. Baldus, Jerry D. Clark, Albert D. Edeny, Patrick H. Lau, Daniel R. Dukesherer, Lisa McDermott, Michael K. Mao, Gopi Yalamanchili, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine Seymour, Shekhar Viswanath, John K. Walker
  • Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
    Publication number: 20050107387
    Abstract: The present invention provides compositions and methods for the treatment of ischemic mediated central nervous system disorders. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder comprising the administration to a subject of a peroxisome proliferator activated receptor agonist in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: May 12, 2004
    Publication date: May 19, 2005
    Applicant: Pharmacia Corporation
    Inventors: Philip Needleman, Mark Obukowicz
  • Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
    Publication number: 20050107350
    Abstract: The present invention describes a novel method for preventing or treating bone disorders and bone disorder-related complications in a subject involving a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a bone disorder treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a bone disorder treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.
    Type: Application
    Filed: August 12, 2004
    Publication date: May 19, 2005
    Applicant: Pharmacia Corporation
    Inventor: Lisa Olson